Alzamend Neuro plans a Phase 2 trial of AL001 for PTSD in late 2025, aiming for better lithium delivery, improved safety, and ...

The stock option granted on November 5, 2024 has a ten-year term and an exercise price of $3.59 per share, which is equal to ...

Cartesian Therapeutics is a clinical-stage company pioneering mRNA cell therapies for the treatment of autoimmune diseases. The Company’s lead asset, Descartes-08, is an mRNA CAR-T in Phase 2b ...

The Inducement Grants have been granted outside ... a pivotal program for veligrotug (VRDN-001), including two global phase 3 clinical trials (THRIVE and THRIVE-2), to evaluate its efficacy ...

The inducement offer calls for holders to exercise their existing warrants at the reduced exercise price of $2.51 per share in exchange for two new warrants to purchase common stock for each ...

PLYMOUTH MEETING, PA — INOVIO Pharmaceuticals Inc. (NASDAQ: INO) has announced the recent award of equity grants to two new employees as part of its 2022 Inducement Plan. The company’s ...

In the phase 3 induction study, patients received either Tremfya 200 mg ... Crohn's disease is one of the two main forms of inflammatory bowel disease, which affects an estimated three million ...

Kura Oncology, Inc. (the “Company”) (Nasdaq: KURA), a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, today announced ...

The option was granted pursuant to the Company’s Amended and Restated 2018 Employment Inducement Incentive Award Plan and was approved by the Company’s board of directors. The option vests as ...